Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Summit Medical Group, P.A.

Neither a doctor nor a teaching hospital

Research payments

$553,570

49 payments

Through program year 2025, Summit Medical Group, P.A. is reported as receiving $553,570 in research payments, across 49 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $493,405 29
2024 Research $21,331 5
2023 Research $5,452 2
2020 Research $3,719 4
2019 Research $29,664 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. BeOne Medicines Ltd. $322,282 15 payments
  2. BeiGene, Ltd. $115,362 9 payments
  3. Calyxo, Inc. $50,294 4 payments
  4. Amgen Inc. $22,269 1 payment
  5. BeiGene USA, Inc. $19,096 1 payment
  6. Gilead Sciences, Inc. $10,285 7 payments
  7. Urogen Pharma, Inc. $5,678 3 payments
  8. BeOne Medicines USA, Inc. $4,700 2 payments
  9. Portola Pharmaceuticals, Inc. $1,484 5 payments
  10. Verastem, Inc. $1,258 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib $424,303 13 payments
  2. Aspire $50,294 4 payments
  3. 6110 and 6200 - OPZ Heme Ph1b/2 Trial (2011-001) $22,269 1 payment
  4. A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia $19,096 1 payment
  5. An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies $10,372 9 payments
  6. Bl011 - A Phase 3 Single-Arm Study of Ugn -102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (Envision) $5,678 3 payments
  7. A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies $4,700 2 payments
  8. A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS 9973 in Subjects with Relapsed or Refractory Hematologic Malignancies $3,355 1 payment
  9. An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) $2,969 2 payments
  10. Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens $2,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record